# Safety and Efficacy of the RENATUS® Transcatheter Aortic Valve System for the Treatment of Severe Aortic Stenosis

Study · id `cardio:ct-nct07414342` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07414342](<https://clinicaltrials.gov/study/NCT07414342>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07414342

Browse, organ or system: Heart  
Browse, condition area: Valve and congenital heart disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 800 participants.

## Technical summary

Registry record NCT07414342. Allocation not applicable; no masking; primary purpose treatment. Start 2026-02 (anticipated); primary completion 2027-09 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 800 participants (planned count; ClinicalTrials.gov record NCT07414342, source copy `cardio:ctgov-nct07414342-2026-02-17`, retrieved 2026-10-26)
- Planned start: 2026-02 (anticipated) (ClinicalTrials.gov record NCT07414342, source copy `cardio:ctgov-nct07414342-2026-02-17`, retrieved 2026-10-26)
- Primary completion: 2027-09 (anticipated) (ClinicalTrials.gov record NCT07414342, source copy `cardio:ctgov-nct07414342-2026-02-17`, retrieved 2026-10-26)
- Completion: 2037-09 (anticipated) (ClinicalTrials.gov record NCT07414342, source copy `cardio:ctgov-nct07414342-2026-02-17`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT07414342, source copy `cardio:ctgov-nct07414342-2026-02-17`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07414342-2026-02-17`, retrieved 2026-10-26)

## The registry's words

- Brief title: Safety and Efficacy of the RENATUS® Transcatheter Aortic Valve System for the Treatment of Severe Aortic Stenosis
- Condition: Severe Aortic Stenosis
- Intervention (Device): RENATUS® TAVR
- Lead sponsor: Beijing Balance Medical Technology Co., Ltd
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Aortic stenosis (`cardio:aortic-stenosis`)
- Registry condition terms include this condition: Heart valve disease (`cardio:heart-valve-disease`)

## Provenance

Content hash: 7a3c51bc5a6e020839587f7b97a7e3dff926f30a35644aec8b3c0a40c1501ce1
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
